当前位置： SCI文献检索 > PSYCHOPHARMACOLOGY期刊下所有文献 > Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Abstract：

:Preclinical studies have exploded our knowledge about the behavioral and biological underpinnings of alcoholism. These studies suggest that certain neurotransmitters, particularly those interacting with the opioid, N-methyl-D-aspartate, and monoamine systems, may play a critical role in the expression of alcohol-drinking and other behaviors associated with its abuse liability. Built upon this foundation, important advances have been made in the development of therapeutic medications for the treatment of alcoholism. Of the medications reviewed, acamprosate's potential appears to be the most widely established. In the USA, naltrexone was approved by the Food and Drug Administration in 1995 for the treatment of alcoholism; however, the results of some studies have been less encouraging. Naltrexone's reliance on high compliance rates for efficacy may, eventually, limit its potential in clinical settings offering generic treatment for alcoholism. The relative paucity of dose-response studies on naltrexone's effects in treating alcoholics is an important gap in the literature. Recent data from a large clinical trial suggests that ondansetron, a serotonin3 antagonist, offers new hope for the treatment of early onset alcoholics; a type of alcoholism most difficult to manage with psychosocial measures alone. Different subtypes of alcoholic may, therefore, have varying treatment responses to serotonergic agents. Matching subtypes of alcoholic to effective treatment medications based upon their different biologies remains an important therapeutic goal. Combinations of effective pharmacological agents need exploration as they may prove to be synergistic, and could shepherd in a new era of treatments aimed at multiple neurotransmitter targets associated with the alcoholism disease. The coming decade promises more powerful tools for characterizing drug effects on alcohol drinking, thereby closing the gap between animal models of addiction and the human condition.

journal_name

Psychopharmacology (Berl)

journal_title

Psychopharmacology

authors

Johnson BA,Ait-Daoud N

doi

10.1007/s002130000371

subject

Has Abstract

pub_date

2000-05-01 00:00:00

pages

327-44

issue

eissn

0033-3158

issn

1432-2072

journal_volume

149

pub_type

杂志文章,评审

在线工具

Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.